PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
25889879-9	2015	However, FK506 and tat-VIVIT significantly attenuated both microgliosis and Abeta plaque load in treated mice compared to controls.	Tacrolimus	9-14	amyloid beta (A4) precursor protein	Mus musculus	76-81	
20847451-0	2010	FK506 reduces amyloid plaque burden and induces MMP-9 in AbetaPP/PS1 double transgenic mice.	Tacrolimus	0-5	amyloid beta (A4) precursor protein	Mus musculus	57-64	
20847451-4	2010	Treatment with FK506, a CaN inhibitor, significantly reduces Abeta burden and restores synaptic proteins (synaptophysin and postsynaptic density protein-95; PSD-95) while inducing matrix metallopeptidase-9 (MMP-9) expression in GFAP-positive astrocytes in the brain.	Tacrolimus	15-20	amyloid beta (A4) precursor protein	Mus musculus	61-66	
20847451-5	2010	These results suggest a role of FK506 and control of CaN activity in neuroprotection associated with Abeta deposition in AD.	Tacrolimus	32-37	amyloid beta (A4) precursor protein	Mus musculus	101-106